9ARV

CryoEM structure of AMETA-A3

9ARV の概要

• エントリーDOI: 10.2210/pdb9arv/pdb
• EMDBエントリー: 43795
• 分子名称: Isoform 1 of Immunoglobulin heavy constant mu, Immunoglobulin J chain, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
• 機能のキーワード: igm, nanobody, immune system
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 11
• 化学式量合計: 431854.46

構造登録者

Huang, W.,Sang, Z.,Taylor, D. (登録日: 2024-02-23, 公開日: 2024-11-06, 最終更新日: 2024-12-11)

主引用文献

Xiang, Y.,Xu, J.,McGovern, B.L.,Ranzenigo, A.,Huang, W.,Sang, Z.,Shen, J.,Diaz-Tapia, R.,Pham, N.D.,Teunissen, A.J.P.,Rodriguez, M.L.,Benjamin, J.,Taylor, D.J.,van Leent, M.M.T.,White, K.M.,Garcia-Sastre, A.,Zhang, P.,Shi, Y.
Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy.
Cell, 187:6966-6980.e23, 2024

PubMed Abstract: Pathogens constantly evolve and can develop mutations that evade host immunity and treatment. Addressing these escape mechanisms requires targeting evolutionarily conserved vulnerabilities, as mutations in these regions often impose fitness costs. We introduce adaptive multi-epitope targeting with enhanced avidity (AMETA), a modular and multivalent nanobody platform that conjugates potent bispecific nanobodies to a human immunoglobulin M (IgM) scaffold. AMETA can display 20+ nanobodies, enabling superior avidity binding to multiple conserved and neutralizing epitopes. By leveraging multi-epitope SARS-CoV-2 nanobodies and structure-guided design, AMETA constructs exponentially enhance antiviral potency, surpassing monomeric nanobodies by over a million-fold. These constructs demonstrate ultrapotent, broad, and durable efficacy against pathogenic sarbecoviruses, including Omicron sublineages, with robust preclinical results. Structural analysis through cryoelectron microscopy and modeling has uncovered multiple antiviral mechanisms within a single construct. At picomolar to nanomolar concentrations, AMETA efficiently induces inter-spike and inter-virus cross-linking, promoting spike post-fusion and striking viral disarmament. AMETA's modularity enables rapid, cost-effective production and adaptation to evolving pathogens.

PubMed: 39447570
DOI: 10.1016/j.cell.2024.09.043

実験手法

ELECTRON MICROSCOPY (3.6 Å)